MARKET

PGNX

PGNX

Progenics Pharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.690
-0.020
-0.42%
After Hours: 4.690 0 0.00% 16:00 01/17 EST
OPEN
4.780
PREV CLOSE
4.710
HIGH
4.780
LOW
4.620
VOLUME
357.32K
TURNOVER
--
52 WEEK HIGH
6.37
52 WEEK LOW
3.420
MARKET CAP
405.32M
P/E (TTM)
-5.5490
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of PGNX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

PGNX News

  • Progenics Pharmaceuticals Announces Presentation at the 2020 SNMMI Mid-Winter Meeting
  • GlobeNewswire.3d ago
  • IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Progenics Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
  • ACCESSWIRE.4d ago
  • INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Progenics Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
  • ACCESSWIRE.01/11 02:30
  • ONGOING SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Progenics Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  • ACCESSWIRE.01/09 02:55

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About PGNX

Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation. AZEDRA is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands, respectively. RELISTOR is a treatment for opioid induced constipation. PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer. PSMA TTC is a thorium-227 labeled PSMA-targeted antibody therapeutic.
More

Webull offers Progenics Pharmaceuticals, Inc. (PGNX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.